Modulation of ciliogenesis
AssigneeAcademisch Ziekenhuis Leiden a/u Leiden University Medical Center
InventorRonald Karel Louisa Van Brempt
Life of this patent
Estimating the term…
Abstract
The disclosure is based on the finding that compounds capable of binding to (or interacting with) chromatin binding/remodelling complexes (for example Polycomb group PRC1 and Trithorax group MLL) and/or modulation of the same can be used to modulate (for example switch on/off) ciliogenesis as may occur, for example, in the human pulmonary bronchial epithelium. Provided are compounds, compositions, methods and medicaments which may be used to treat and/or prevent diseases and/or conditions associated with aberrant or defective ciliogenesis.
Claims5
A method of treating diseases and/or conditions of the pulmonary system and/or airways caused by a loss of ciliogenesis, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound comprising an antisense oligonucleotide or an RNAi type inhibitor that reduces, inhibits and/or ablates the expression, function and/or activity of the R2R1 gene, thereby treating the diseases and/or conditions of the pulmonary system and/or airways caused by a loss of ciliogenesis.
Dependencies are inferred from the claim text.